Yau T, Kang Y-K, Kim T-Y, El-Khoueiry A, Santoro A, Sangro B, Melero I, Kudo M, Hou M-M, Matilla A, Tovoli F, Knox J, He A, El-Rayes B, Acosta-Rivera M, Lim H-Y, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6(11):e204564. PMCID: PMC7530824

Yau T, Hsu C, Kim T-Y, Choo S-P, Kang Y-K, Hou M-M, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz C, Kudo M. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543–552. PMID: 31176752

Satoh T, Kang Y-K, Chao Y, Ryu M-H, Kato K, Chung H, Chen J-S, Muro K, Kang W, Yeh K-H, Yoshikawa T, Oh S, Bai L-Y, Tamura T, Lee K-W, Hamamoto Y, Kim J, Chin K, Oh D-Y, Minashi K, Cho J, Tsuda M, Tanimoto M, Chen L-T, Boku N. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2020;23(1):143–153. PMCID: PMC6942596